Abstract
In the past several decades, increased regulation of the drug and device industry has significantly impacted the way manufacturers develop, manufacture, market and monitor medical products. As the distribution of medical products expands globally, so also the need for industry and regulators to understand product safety and performance on a world-wide basis. The resulting depth and specificity of quality system requirements have led to significant demands on both industry and governmental agencies.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsPreview
Unable to display preview. Download preview PDF.
References
O’Leary D. Quality assessment: moving from theory to practice. J Am Med Assoc 1988; 260:1760.
Sauer F. A new and fast drug approval system in Europe. Drug Inf J 1997; 31:1–6.
Jones K. Wider perspectives of European medicines control. Drug Inf J 1996; 30:1–7.
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1999 Kluwer Academic Publishers.
About this chapter
Cite this chapter
McDonnell, P., Thuma, R.S. (1999). The impact of global vigilance reporting requirements on the quality of dialysis products and services. In: Henderson, L.W., Thuma, R.S. (eds) Quality Assurance in Dialysis. Developments in Nephrology, vol 39. Springer, Dordrecht. https://doi.org/10.1007/978-0-585-28312-8_8
Download citation
DOI: https://doi.org/10.1007/978-0-585-28312-8_8
Publisher Name: Springer, Dordrecht
Print ISBN: 978-0-7923-5281-5
Online ISBN: 978-0-585-28312-8
eBook Packages: Springer Book Archive